• Kymera Therapeutics Inc KYMR.OQ KYMR.O is expected to show a fall in quarterly revenue when it reports results on February 27 for the period ending December 31 2024

• The Watertown Massachusetts-based company is expected to report a 75.3% decrease in revenue to $11.82 million from $47.88 million a year ago, according to the mean estimate from 17 analysts, based on LSEG data.

• ​LSEG's mean analyst estimate for Kymera Therapeutics Inc is for a loss of 77 cents per share.

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell."

• The mean earnings estimate of analysts was unchanged in the last three months. ​

• Wall Street's median 12-month price target for Kymera Therapeutics Inc is $57.00​, above​ its last closing price of $35.31. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

This summary was machine generated February 25 at 14:22 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)